Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in Advanced Osteosarcoma and Soft Tissue Sarcoma
NCT05106777Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in osteosarcoma (OS), soft tissue sarcoma (STS), sponsored by Sun Yat-sen University. Started Dec 2021; status: active, not recruiting.
02
Drugs
surufatinib
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05106777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106777.